Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion

Background. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show low-response to treatment with regard to visual acuity gain (VA) and OCT central retinal thickness (CRT) reduction. The goal of this study was to quantify the percentage of lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Menke, Marcel N., Ebneter, Andreas, Zinkernagel, Martin S., Wolf, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156818/
https://www.ncbi.nlm.nih.gov/pubmed/28044102
http://dx.doi.org/10.1155/2016/9875741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156818/
https://www.ncbi.nlm.nih.gov/pubmed/28044102
http://dx.doi.org/10.1155/2016/9875741

Ejemplares similares